WEC
ITCI

Winslow Evans & Crocker’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Winslow Evans & Crocker’s Portfolio ITCI Stock Details ITCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		$8K Hold
240
– – ﹤0.01% 1006
2020
Q3 		$6K Hold
240
– – ﹤0.01% 864
2020
Q2 		$6K Hold
240
– – ﹤0.01% 864
2020
Q1 		$4K Hold
240
– – ﹤0.01% 958
2019
Q4 		$10K Hold
240
– – ﹤0.01% 837
2019
Q3 		$2K Hold
240
– – ﹤0.01% 1120
2019
Q2 		$4K Buy
+240
New +$3.08K ﹤0.01% 1037

Other funds holding ITCI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
SC
Samlyn Capital New York $5.86B AUM 36.3% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Winslow Evans & Crocker's ITCI Position: Q4 2020 in Review

Winslow Evans & Crocker held its Intra-Cellular Therapies Inc. (ITCI) position steady in Q4 2020 at 240 shares worth $8K. The position accounts for ﹤0.01% of the portfolio, ranked #1006.

Winslow Evans & Crocker first reported a position in ITCI in Q2 2019 and has held it in 7 quarters since. The position peaked at $10K in Q4 2019. 178 funds tracked by Wall St. Rank hold ITCI as of Q4 2020.

  • Winslow Evans & Crocker held 240 shares of Intra-Cellular Therapies Inc. worth $8K as of Q4 2020.
  • Winslow Evans & Crocker left its Intra-Cellular Therapies Inc. share count unchanged in Q4 2020.
  • Intra-Cellular Therapies Inc. made up ﹤0.01% of Winslow Evans & Crocker's portfolio in Q4 2020, its #1006 holding.
  • Winslow Evans & Crocker first reported a position in Intra-Cellular Therapies Inc. in Q2 2019 and has held it in 7 quarters since.
  • Winslow Evans & Crocker's Intra-Cellular Therapies Inc. position peaked at $10K in Q4 2019.
  • 178 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q4 2020.

Based on Winslow Evans & Crocker's 13F filing for Q4 2020, filed 3 Feb 2021.